Researchers Have Concerns About Pfizer, Merck’s COVID-19 Pill Being Resistant To COVID-19 Mutations

From SeekingAlpha.com…

• Pfizer (NYSE:PFE) and Merck (NYSE:MRK), the developers of the first oral medications for COVID-19 in the U.S., are advancing combinationstudies for their antiviral therapies as experts flag the risk of viral resistance to the newly authorized pills, The Wall Street Journalreports.

 

• Last month, the FDA greenlighted Paxlovid from Pfizer (PFE) and molnupiravir from Merck (MRK)/ Ridgeback Biotherapeutics as the first oral COVID-19 therapies for at-home use.

 

• However, the mutations that allow viruses to evade the antivirals are a real danger for drugs like Paxlovid and molnupiravir, which are given alone for patients, unlike the combination regimens used in infections, such as HIV and hepatitis C.

Read More